Lebenthal Global Advisors LLC Has $714,000 Stake in Pfizer Inc. (NYSE:PFE)

Lebenthal Global Advisors LLC grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 40.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 26,901 shares of the biopharmaceutical company’s stock after acquiring an additional 7,765 shares during the period. Lebenthal Global Advisors LLC’s holdings in Pfizer were worth $714,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in PFE. Foundations Investment Advisors LLC grew its stake in Pfizer by 43.6% during the fourth quarter. Foundations Investment Advisors LLC now owns 118,998 shares of the biopharmaceutical company’s stock worth $3,157,000 after purchasing an additional 36,145 shares during the period. Parsons Capital Management Inc. RI boosted its holdings in shares of Pfizer by 118.7% during the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company’s stock worth $7,820,000 after buying an additional 159,984 shares in the last quarter. Pacer Advisors Inc. grew its position in shares of Pfizer by 386.0% during the 4th quarter. Pacer Advisors Inc. now owns 2,095,900 shares of the biopharmaceutical company’s stock worth $55,604,000 after buying an additional 1,664,668 shares during the period. Center For Asset Management LLC increased its stake in shares of Pfizer by 3.7% in the 4th quarter. Center For Asset Management LLC now owns 35,052 shares of the biopharmaceutical company’s stock valued at $930,000 after acquiring an additional 1,243 shares in the last quarter. Finally, KBC Group NV lifted its position in shares of Pfizer by 6.3% during the 4th quarter. KBC Group NV now owns 3,301,369 shares of the biopharmaceutical company’s stock valued at $87,586,000 after acquiring an additional 195,936 shares during the period. 68.36% of the stock is owned by institutional investors.

Insider Transactions at Pfizer

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The shares were acquired at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the acquisition, the director now owns 10,000 shares of the company’s stock, valued at $282,400. The trade was a 11.11 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on PFE shares. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Guggenheim reduced their target price on Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Citigroup began coverage on Pfizer in a research note on Friday, October 25th. They set a “neutral” rating and a $30.00 price target on the stock. Truist Financial reduced their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Wednesday, October 23rd. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $32.00.

Pfizer Price Performance

Shares of NYSE:PFE opened at $26.86 on Tuesday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The stock has a market cap of $152.19 billion, a PE ratio of 36.29, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The stock’s fifty day simple moving average is $26.11 and its two-hundred day simple moving average is $27.94. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. During the same period last year, the firm earned ($0.17) earnings per share. The firm’s revenue was up 31.2% on a year-over-year basis. As a group, analysts forecast that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.40%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is currently 227.03%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.